IMMUNOGEN sees an upgrade to Slightly Positive due to a better fundamental star rating
The general evaluation of IMMUNOGEN (US), a company active in the Biotechnology industry, has been upgraded by the independent financial analyst theScreener with the addition of a star. Its fundamental valuation now shows 3 out of 4 possible stars while its market behaviour can be considered as moderately risky. theScreener believes that the additional star(s) merits the upgrade of its general evaluation to Slightly Positive. As of the analysis date March 18, 2022, the closing price was USD 5.26 and its potential was estimated at USD 7.23.ImmunoGen is a clinical-stage biotechnology company focused on developing antibody-drug conjugates (ADCs). An ADC with the company's proprietary technology comprises an antibody that binds to a target found on tumor cells and is conjugated to one of its anti-cancer agents as a payload to kill the tumor cell once the ADC has bound to its target. The company's main program is mirvetuximab soravtansine, an ADC targeting folate-receptor alpha, a cell-surface protein overexpressed in a number of epithelial tumors, including ovarian, endometrial, and non-small-cell lung cancers. The company is developing IMGN632 in clinical trials for patients with acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm.
Empowering Investors
theScreener is the market leader for independent valuations of financial securities, equities, sectors and markets, and new funds. theScreener's ratings, analyses are used by leading banks, asset managers and financial portals. Approximately 10,000 workstations benefit from theScreener's services, with over millions of customer accounts actively analysed.
- Worldwide coverage: theScreener analyses cover around 6'500 Stocks, i.e 95% of the world Market Capitalization. theScreener state of art: We provide
- theScreener state of art: We provide easy to use and complete analyses over Stocks, including Fundamentals / Technical / Risk/ Peer / Alternatives analyses.
- For Research Pool community, we provide twice a week around 500 new equity analyses. We produce analyses about equities which have been upgraded or downgraded.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.